

# Table 1

	<b>Pain with neuropathic characteristics (n=346)</b>	<b>Pain without neuropathic characteristics (n=143)</b>	<b>Odds Ratio (CI95%)</b>	<b>p value</b>
<b>DN-4 score</b>	4.5 ± 0.1	1.5 ± 0.1		<0.001
<b>Female : % (n)</b>	81.8 (283)	77.6 (111)	1.18 (0.75 – 1.85)	0.284
<b>Age (years)</b>	48.9 ± 0.6	50.7 ± 1.1		0.162
<b>Time from onset (years)</b>	13.7 ± 0.5	15.3 ± 0.9		0.122
<b>RR-MS : %</b>	73.4	67.2	1.28 (0.83 – 1.96)	0.260
<b>Pain Severity Index (/10)</b>	4.9 ± 0.1	3.9 ± 0.2		<0.001
<b>Pain descriptors (%)</b>				
<b>Burning</b>	59.7	16.2	7.69 (4.67 – 12.59)	<0.001
<b>Painful cold</b>	44.9	12.0	6.00 (3.46 – 10.39)	<0.001
<b>Electric shock</b>	72.2	29.6	6.18 (4.02 – 9.50)	<0.001
<b>Tingling</b>	83.2	28.2	<b>12.62</b> (7.95 – 20.02)	<0.001
<b>Pins and needles</b>	61.2	4.2	<b>35.69</b> (15.32 – 83.15)	<0.001
<b>Itching</b>	33.9	7.0	6.77 (3.43 – 13.38)	<0.001
<b>Numbness</b>	89.9	49.3	9.11 (5.64 – 14.72)	<0.001
<b>Pain locations (%)</b>				
<b>Head</b>	38.3	17.3	2.99 (1.83 – 4.89)	<0.001
<b>Neck/shoulder</b>	34.6	14.4	3.16 (1.87 – 5.33)	<0.001
<b>Upper limb</b>	68.0	34.5	4.07 (2.68 – 6.17)	<0.001
<b>Thorax</b>	11.2	1.4	8.70 (2.07 – 36.53)	<0.001
<b>Abdomen</b>	12.1	6.5	2.00 (0.94 – 4.22)	0.071
<b>Back</b>	43.8	35.3	1.44 (0.96 – 2.16)	0.080
<b>Lower limb</b>	88.5	75.5	2.55 (1.53 – 4.25)	<0.001
<b>3 or more locations : % (n)</b>	58.2 (202)	18.9 (27)	7.89 (4.96 – 12.53)	<0.001
<b>Pain Interference Index (/10)</b>	5.6 ± 0.2	4.9 ± 0.3		0.028
<b>EDSS</b>	3.7 ± 0.1	3.8 ± 0.2		0.365
<b>Migraine : % (n)</b>	62.0 (215)	42.7 (61)	6.62 (3.40 - 10.85)	<0.001
<b>Catastrophizing (/52)</b>	24.5 ± 0.7	20.0 ± 1.1		<0.001

# Table 2

Treatments		Migraine	No	Migraine	No	Probable
		+ pain with NC (n=215)	migraine + pain with NC (n=131)	+ no pain with NC (n=94)	migraine + no pain with NC (n=89)	migraine ≥15 days per month (n=45)
<b>First step ladder</b>	Paracetamol	135	59	48	28	30
	NSAID	46	14	13	8	12
	SAID	4	1	0	1	1
	Nefopam	1	0	0	2	1
<b>Second step ladder</b>	Tramadol	20	6	4	5	8
	Codeine	0	1	0	0	0
	Opium + Caffeine	8	1	0	0	4
	Dextropropoxyphene	7	6	4	1	0
<b>Third step ladder</b>	Morphine/ Fentanyl/ Oxycodone	3	0	0	1	1
	<b>Antidepressant drugs</b>	23	17	1	6	6
<b>Antiepileptic drugs</b>		34	25	6	10	5
<b>Specific migraine attacks treatments</b>	Triptans	8	1	3	0	1
	Dihydroergotamine	4	0	0	1	2
<b>Antispastic drugs (baclofene, dantrolene)</b>		15	21	2	12	3

# Table 3

	Migraine (n=309)	No migraine (n=220)	p
<b>Female: % (n)</b>	83.5 (258)	77.3 (170)	0.073
<b>Age (years)</b>	46.2 ± 0.7	52,7 ± 0.7	<0.001
<b>Time from onset (years)</b>	12.1 ± 0.5	16,6 ± 0.7	<0.001
<b>RR-MS : %</b>	78.8	61.7	<0.001
<b>Headache pain (/10)</b>	6.0 ± 0.1	1.1 ± 0.1	<0.001
<b>Days per month with headaches</b>	8.4 ± 0.4	1.2 ± 0.3	<0.001
<b>Chronic headache (&gt;14 days per month): %</b>	14.6 (45)	1.8 (4)	<0.001
<b>3 or more pain locations : % (n)</b>	40.5 (125)	47.3 (104)	0.118
<b>EDSS</b>	3.3 ± 0.1	4.1 ± 0.2	<0.001
<b>Pain Interference Index (/10)</b>	5.4 ± 0.2	5.2 ± 0.2	0.464
<b>Catastrophizing (/52)</b>	24.3 ± 0.8	20.9 ± 0.8	0.002
<b>Pain with NC (DN4≥3/7) : %</b>	69.6	59.7	0.019
<b>Receiving beta interferon : % (n/available data)</b>	35.0 (69/197)	24.8 (38/153)	0.040

# Table 4

	<b>Migraine + pain with NC (n=215)</b>	<b>No migraine + pain with NC (n=131)</b>	<b>Migraine + no pain with NC (n=94)</b>	<b>No migraine + no pain with NC (n=89)</b>
<b>Female: % (n)</b>	83.7 (180)	78.6 (103)	83.0 (78)	75.3 (67)
<b>Age (years)</b>	46.6 ± 0.8	52.9 ± 0.9	45.5 ± 1.4	52.3 ± 1.2
<b>Time from onset (years)</b>	11.7 ± 0.6	16.8 ± 1.0	13.1 ± 1.0	16.2 ± 1.1
<b>RR-MS: %</b>	80.2	61.7	74.7	61.8
<b>Headache pain (/10)</b>	6.2 ± 0.1	1.2 ± 0.2	5.3 ± 0.2	1.0 ± 0.2
<b>Pain Severity Index (/10)</b>	5.9 ± 0.1	5.2 ± 0.2	3.3 ± 0.3	4.3 ± 2.3
<b>3 or more pain locations: % (n)</b>	51.2 (110)	69.7 (92)	16.0 (15)	13.5 (12)
<b>Pain Interference Index (/10)</b>	5.1 ± 0.1	4.5 ± 0.2	2.8 ± 0.3	3.7 ± 0.3
<b>EDSS</b>	3.5 ± 0.2	4.1 ± 0.2	2.9 ± 0.2	4.2 ± 0.2
<b>Catastrophizing (/52)</b>	25.9 ± 0.9	22.1 ± 1.0	14.1 ± 1.5	19.9 ± 1.5

# Table 5

A-

	<10 years (n=208)	10 to 19 years (n=214)	> 20 years (n=146)	Statistical comparisons
<b>Pain : % (n)</b>	83.7 (174)	78.5 (168)	76.7 (112)	NS
<b>Headaches : % (n)</b>	61.5 (128)	57.5 (123)	39.7 (58)	A≠C and B≠C
<b>Migraine : % (n)</b>	54.3 (113)	50.9 (109)	28.8 (42)	A≠C and B≠C
<b>Painful body sites ≥3: % (n)</b>	34.1 (71)	36.9 (79)	29.5 (43)	NS
<b>Neuropathic characteristics: % (n)</b>	55.8 (116)	53.3 (114)	47.3 (69)	NS
<b>Pain without neuropathic characteristics: % (n)</b>	19.7 (41)	20.6 (44)	23.3 (34)	NS

B-

	≤ 35 years old (n= 84)	36 to 54 years old (n= 346)	≥ 55 years old (n= 243)	Statistical comparisons
<b>Female : % (n)</b>	82.1 (69)	78.6 (272)	79.4 (193)	NS
<b>RR-MS: %</b>	96	82.3	38.2	A≠B≠C
<b>EDSS</b>	1.56±0.2	3.1±0.1	5.3±0.1	A≠B≠C
<b>Pain : % (n)</b>	83.3 (70)	80.9 (280)	73.7 (179)	NS
<b>Headaches : % (n)</b>	76.2 (64)	56.6 (196)	41.6 (101)	A≠B≠C
<b>Migraine : % (n)</b>	67.9 (57)	49.7 (172)	32.9 (80)	A≠B≠C
<b>Painful body sites ≥3: % (n)</b>	31.0 (26)	40.5 (140)	25.9 (63)	B≠C
<b>Neuropathic characteristics: % (n)</b>	44.0 (37)	56.9 (197)	46.1 (112)	A≠B and B≠C
<b>Pain without neuropathic characteristics: % (n)</b>	21.4 (18)	19.4 (67)	23.9 (58)	B≠C

## Table 6

<b>Sub-group of patients with known disease modifying treatment</b>	<b>399</b>
<b>No treatment</b>	<b>146</b>
<b>Glatiramer acetate</b>	<b>55</b>
<b>Beta 1 a interferon (intramuscular)</b>	<b>47</b>
<b>Beta 1 a interferon (sub cutaneous)</b>	<b>37</b>
<b>Beta 1 b interferon</b>	<b>36</b>
<b>Natalizumab</b>	<b>31</b>
<b>Methotrexate</b>	<b>27</b>
<b>Clinical trials (finategrast®, laquinimod®, teriflunomide®)</b>	<b>7</b>
<b>Cyclophosphamide</b>	<b>5</b>
<b>Micophenolate mofetil</b>	<b>4</b>
<b>Mitoxantrone</b>	<b>3</b>
<b>Methylprednisolone</b>	<b>1</b>